VistaGen Therapeutics Inc VTGN:NASDAQ

Last Price$0.18NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/11/22

Today's Change+0.004(2.40%)
Bid (Size)$0.16 (1)
Ask (Size)$0.17 (173)
Day Low / High$0.17 - 0.19
Volume8.1 K
 

View Biotechnology IndustryPeer Comparison as of 08/11/2022

 

VistaGen Therapeutics Inc ( NASDAQ )

Price: $0.18
Change: +0.004 (2.40%)
Volume: 8.1 K
4:00PM ET 8/11/2022
 
 

Larimar Therapeutics Inc ( NASDAQ )

Price: $1.98
Change: +0.02 (1.02%)
Volume: 80.1 K
4:00PM ET 8/11/2022
 
 

Microbot Medical Inc ( NASDAQ )

Price: $5.25
Change: +0.04 (0.74%)
Volume: 14.9 K
3:59PM ET 8/11/2022
 
 

Aikido Pharma Inc ( NASDAQ )

Price: $6.10
Change: -0.22 (3.48%)
Volume: 50.7 K
4:00PM ET 8/11/2022
 
 

Caladrius Biosciences Inc ( NASDAQ )

Price: $0.53
Change: +0.008 (1.51%)
Volume: 272.7 K
3:32PM ET 8/11/2022
 

Read more news Recent News

--Maxim Downgrades VistaGen Therapeutics to Hold From Buy
9:17AM ET 7/26/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Midday Decliners
2:01PM ET 7/22/2022 MT Newswires

VistaGen Therapeutics (VTGN) said a late-stage trial of its investigational drug PH94B for the acute treatment of anxiety in individuals who suffer from...

--Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8
12:24PM ET 7/22/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform
10:29AM ET 7/22/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. View company web site for more details
Address343 Allerton Avenue
South San Francisco, California 94080
Phone+1.650.577.3600
Number of Employees9
Recent SEC Filing08/11/20228-K
Chief Executive Officer & DirectorShawn K. Singh
Chief Financial Officer, Secretary & VPJerrold D. Dotson
Chief Medical OfficerMark A. Smith
Vice President-Global Clinical OperationsEllis Wilson

Company Highlights

Price Open$0.17
Previous Close$0.18
52 Week Range$0.14 - 3.26
Market Capitalization$36.2 M
Shares Outstanding206.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.24
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-4,306.76%
Return on Equity-61.44%

Analyst Ratings as of 07/25/2022

Buy
1
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset